Amgen Inc. (NASDAQ:AMGN) is identified as one of the most undervalued low volatility stocks to buy, with Piper Sandler raising its price target to $342 from $328. The firm cites Amgen’s strong execution and pipeline advancement as reasons for potential multiple expansion in the future.

Amgen Inc. (NASDAQ:AMGN) is a biotechnology company specializing in human therapeutics, particularly in treating complex cancers. Despite its investment potential, other AI stocks are seen as offering greater upside and lower downside risk in the market.

Following its quarterly results, Amgen Inc. (NASDAQ:AMGN) is praised for its ability to overcome the loss of exclusivity for denosumab through strong commercial performance and pipeline advancements. The firm maintains an Overweight rating on the company’s shares.

Read more at Yahoo Finance: Piper Sandler Lifts PT on Amgen (AMGN) to $342 From $328, Keeps an Overweight Rating